10x Genomics is trading 14.62% down at $70.08, with broad market weakness the most likely context; no company-specific announcement explaining the decline was identified. - Reuters reported a broad technology selloff on October 30 as Amazon’s AI spending plans and Intel’s cash-burn warning deepened concerns about AI investment costs and returns; the Nasdaq Composite was down 2.26% at the open. - 10x Genomics is scheduled to report third-quarter results on November 5.